Xilio Therapeutics Doses First Patient in Phase 1/2 XTX501 Trial
Xilio Therapeutics said the first patient has been dosed in its Phase 1/2 clinical trial of XTX501 in patients with metastatic NSCLC.
Xilio Therapeutics said the first patient has been dosed in its Phase 1/2 clinical trial of XTX501 in patients with metastatic NSCLC.